You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Niflumic acid
Niflumic acid is a nonsteroidal anti-inflammatory drug (NSAID); selectively inhibits COX-2. Also activates human TRPA1 inducibly expressed in HEK293 cells; displays agonist activity at GPR35.
Technical Data for Niflumic acid
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Niflumic acid
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Niflumic acid
The following data is based on the product molecular weight 282.22. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.54 mL||17.72 mL||35.43 mL|
|5 mM||0.71 mL||3.54 mL||7.09 mL|
|10 mM||0.35 mL||1.77 mL||3.54 mL|
|50 mM||0.07 mL||0.35 mL||0.71 mL|
References for Niflumic acid
References are publications that support the biological activity of the product.
Ottolia and Toro (1994) Potentiation of large conductance KCa channels by niflumic, flufenamic and mefenamic acids. Biophys.J. 67 2272 PMID: 7535111
Famaey (1997) In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm.Res. 46 437 PMID: 9427063
Hu et al (2010) Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs. Pflugers Arch. 459 579 PMID: 19888597
Deng et al (2012) Multiple tyrosine metabolites are GPR35 agonists. Sci.Rep. 2 373 PMID: 22523636
If you know of a relevant reference for Niflumic acid, please let us know.
View Related Products by Product Action
Keywords: Niflumic acid, Niflumic acid supplier, cyclooxygenase, 2, cox-2, inhibitors, inhibits, Cyclooxygenase, GPR35, 4112, Tocris Bioscience
2 Citations for Niflumic acid
Citations are publications that use Tocris products. Selected citations for Niflumic acid include:
Amjad et al (2015) Conditional knockout of TMEM16A/anoctamin1 abolishes the calcium-activated chloride current in mouse vomeronasal sensory neurons. J Gen Physiol 145 285 PMID: 25779870
Cao et al (2014) SLC17A9 protein functions as a lysosomal ATP transporter and regulates cell viability. J Neuroinflammation 289 23189 PMID: 24962569
Do you know of a great paper that uses Niflumic acid from Tocris? Please let us know.
Reviews for Niflumic acid
Average Rating: 5 (Based on 1 Review.)
Have you used Niflumic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Non-selective cationic current was measured in guinea pig cardiomyocytes before and after superfusion with 100 µM niflumic acid for 10 min. Compared to time matched rundown, niflumic acid significantly increased inward as well as outward non-selective cationic current in cardiomyocytes.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.